



Contact: Gary Nash  
CEOcast, Inc.  
212-732-4300  
gnash@ceocast.com

## **IMMUNOCELLULAR THERAPEUTICS TO PRESENT AT SOUTHERN CALIFORNIA INVESTOR CONFERENCE**

**LOS ANGELES, CA – August 17, 2009** – ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC ), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it will participate in the Southern California Investor Conference being held in Newport Beach, CA, on Tuesday August 18, 2009. IMUC’s President and Chief Executive Officer, Manish Singh, Ph.D., will present an overview of the Company’s business and strategy at 1:45pm at the Island Hotel in Newport Beach.

A webcast of this presentation will be available live and by replay. To access both the live and archived webcasts, as well as the slide presentation used during the conference, please go to [www.imuc.com](http://www.imuc.com).

“We are very pleased to have been invited to present at this prestigious gathering of our region’s most promising up and coming companies,” commented Dr. Singh. “We look forward to having the opportunity to reach a broader investor audience and expect that the occasion will help to significantly raise our exposure to investors who appreciate the type of growth oriented investment that our business presents.”

The conference brings together officers from 30 of Southern California's leading growth oriented companies operating across a breadth of enterprises, including the life sciences, technology, media, and real estate/financial industries with retail and institutional investors from all over the nation.

### About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. The company’s “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials early next year. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit [www.imuc.com](http://www.imuc.com).

## Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risks associated with the timely manufacture of the formulation of the cancer stem cell vaccine for clinical and commercial use and obtaining FDA clearance to commence clinical trials of the cancer stem cell vaccine on a timely basis or at all; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates, including those based on destroying cancer stem cells as a potentially safe and effective treatment for various cancers; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with generating data to support the provisional patent application for the CSC technology and of obtaining a patent that provides commercially significant protection for this technology; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###